ADC Therapeutics SA (ADCT)
NYSE: ADCT · IEX Real-Time Price · USD
4.410
-0.030 (-0.68%)
Apr 26, 2024, 12:51 PM EDT - Market open
ADC Therapeutics Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for ADC Therapeutics stock have an average target of 6.00, with a low estimate of 2.00 and a high estimate of 9.00. The average target predicts an increase of 36.05% from the current stock price of 4.41.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for ADCT stock from 7 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 2 | 2 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 4 | 4 | 4 | 3 | 3 | 3 |
| Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 6 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $9 | Strong Buy | Reiterates | $9 | +104.08% | Apr 15, 2024 |
| Guggenheim | Guggenheim | Strong Buy Reiterates n/a | Strong Buy | Reiterates | n/a | n/a | Apr 5, 2024 |
| Guggenheim | Guggenheim | Strong Buy Initiates $11 | Strong Buy | Initiates | $11 | +149.43% | Mar 28, 2024 |
| RBC Capital | RBC Capital | Buy Reiterates $8 | Buy | Reiterates | $8 | +81.41% | Mar 14, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $9 | Strong Buy | Reiterates | $9 | +104.08% | Mar 6, 2024 |
Financial Forecast
Revenue This Year
82.31M
from 69.56M
Increased by 18.34%
Revenue Next Year
93.68M
from 82.31M
Increased by 13.81%
EPS This Year
-2.19
from -2.94
EPS Next Year
-1.85
from -2.19
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 91.4M | 106.7M | 167.5M | 304.7M | 407.0M |
| Avg | 82.3M | 93.7M | 150.2M | 247.8M | 331.0M |
| Low | 73.1M | 74.4M | 130.2M | 197.3M | 236.5M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 31.3% | 29.6% | 78.8% | 102.9% | 64.2% |
| Avg | 18.3% | 13.8% | 60.3% | 65.0% | 33.5% |
| Low | 5.1% | -9.6% | 39.0% | 31.4% | -4.6% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | -1.81 | -1.59 | -1.08 |
| Avg | -2.19 | -1.85 | -1.38 |
| Low | -2.61 | -2.16 | -1.81 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.